Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
alnylam pharmaceuticals
boston
3
×
boston blog main
boston top stories
clinical trials
life sciences
national blog main
rna interference
aminolevulinic acid
drugs
fda
givosiran
onpattro
patisiran
accelerated approval
acute hepatic porphyria
acute hepatic porphyrias
akcea therapeutics
akin akinc
andrew fire
craig mello
hereditary transthyretin amyloidosis
inotersen
john maraganore
national top stories
new york blog main
new york top stories
nobel prize
paul matteis
pfizer
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
stifel financial
tafamidis
vyndaqel
What
alnylam
drug
medicine
pharmaceuticals
3
×
rnai
3
×
fda
interference
ok
rna
second
seek
speedy
afternoon
ago
alnylam’s
approval
approved
cleared
data
far
gets
history
indicated
landmark
making
market
nasdaq
new
nod
onpattro
patisiran
quick
specifically
weeks
won’t
Language
Current search:
pharmaceuticals
×
rnai
×
boston
×
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug